The main purpose of this study is to test the safety of three study drugs, bevacizumab
(Avastin™), Everolimus (Afinitor™) and LBH589 (Panobinostat) when they are given together. It
is hoped this study drug combination might lead to a greater decrease the in size of the
cancer and/or slow down how fast the cancer is growing compared to when these drugs are given
Subjects will be enrolled at Duke University Medical Center (DUMC).